Gastroparesis Clinical Trials

Find Gastroparesis Clinical Trials Near You

Body Surface Gastric Mapping in Patients With Dyspeptic Symptoms: Recordings at Baseline and on Medical Therapy

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY

Functional dyspepsia and gastroparesis are common stomach disorders with symptoms like early satiety, nausea, and abdominal pain, and are often evaluated with gastric emptying tests, although the correlation with symptoms is weak. Prokinetic agents (e.g., metoclopramide, erythromycin) and symptom modulators (e.g., nortriptyline, mirtazapine) are commonly used, but selecting the right medication can be difficult, as it's often based on symptoms rather than the underlying gastric issues. Body Surface Gastric Mapping (BSGM) using the Gastric Alimetry device is a novel, non-invasive tool to assess gastric myoelectrical activity and symptoms. This study aims to perform two BSGM recordings-one before and one after medical therapy-to understand how medications affect gastric function and identify baseline BSGM factors that could predict responses to treatment, potentially guiding tailored therapies based on individual gastric dysfunction.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients 18 years of age and older

• Diagnosis of gastroparesis and/or functional dyspepsia

• Being prescribed a prokinetic agent or symptom modulator for their clinical care

• Able to undergo BSGM recording both before and during treatment

• Able to give informed consent for undergoing a baseline BSGM recording and an additional recording while on treatment

Locations
United States
Pennsylvania
Temple University
NOT_YET_RECRUITING
Philadelphia
Other Locations
Australia
Western Sydney University
RECRUITING
Sydney
New Zealand
Te Whatu Ora Waitemata
RECRUITING
Auckland
Contact Information
Primary
Genevieve M Johnston, PhD
gen.johnston@auckland.ac.nz
+64 9 373 7599
Time Frame
Start Date: 2025-02-26
Estimated Completion Date: 2028-08-26
Participants
Target number of participants: 125
Treatments
Treatment
Patients undergoing Body Surface Gastric Mapping before and after administration of prescribed prokinetic/neuromodulator
Related Therapeutic Areas
Sponsors
Leads: University of Auckland, New Zealand
Collaborators: Temple University, University of Western Sydney, North Shore Hospital, New Zealand

This content was sourced from clinicaltrials.gov